Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
22 Maio 2023 - 9:30AM
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the
global leader in blood volume measurement technology, today
announced the pricing of its previously announced underwritten
public offering of 410,260 shares of its common stock at a public
offering price of $9.75 per share. Gross proceeds from the offering
are expected to be approximately $4.0 million before deducting
underwriting discounts, commissions, and estimated offering
expenses.
Maxim Group LLC is acting as the sole
book-running manager and Joseph Gunnar & Co., LLC is acting as
co-manager for the offering.
Daxor intends to use the net proceeds from the
offering for working capital and other general corporate purposes,
including to develop our products, fund capital expenditures, make
investments in or acquisitions of other businesses, solutions or
technologies or repay a portion of our outstanding borrowings.
Daxor has granted the underwriters a 45-day
option to purchase up to an additional 61,539 shares of common
stock. The offering is expected to close on or about May 24, 2023,
subject to the satisfaction of customary closing conditions.
A shelf registration statement on Form N-2 (File
Nos. 333-255212 and 811-22684) relating to the securities being
offered was filed with the U.S. Securities and Exchange Commission
(the “SEC”) on April 13, 2021, and became effective on July 16,
2021. The shares may be offered only by means of a prospectus. A
preliminary prospectus supplement and the accompanying prospectus
relating to and describing the terms of the public offering have
been filed with the SEC and are available on the SEC’s website at
www.sec.gov. When available, copies of the preliminary prospectus
supplement and accompanying prospectus relating to the public
offering may also be obtained by contacting Maxim Group LLC, at 300
Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus
Department, or by telephone at (212) 895-3745 or by email at
syndicate@maximgrp.com. Before you invest, you should read the
preliminary prospectus supplement and accompanying prospectus,
together with the information incorporated therein, for more
complete information about Daxor and the proposed offering. The
final terms of the offering will be disclosed in a final prospectus
supplement to be filed with the SEC.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About
Daxor:
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 60,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing multicenter trials in
the areas of COVID-19 and heart failure treatment with support from
the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor’s
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements:
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the timing, size and expected
gross proceeds of the offering, the satisfaction of customary
closing conditions related to the offering and sale of securities,
the grant to the underwriter of an option to purchase additional
shares, and Daxor’s ability to complete the offering.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024